identification of hazards and environmental impact assessment for an integrated approach to emerging risks of co2 capture installations

Abstract New and intensified technologies are being defined within the field of Carbon Capture and Sequestration (CCS) and the uptake is set to increase dramatically. This contribution focuses on three representative installations for CCS capture, whose safety and environmental issues might potentially be underestimated based on their presence in other industrial fields, but with different scales and uses. A simplified Life Cycle Assessment (LCA) and the new hazard identification technique denominated DyPASI (Dynamic Procedure for Atypical Scenarios Identification) were used to identify respectively environmental impact and atypical accident scenarios and add a useful dimension to risk information that can particularly help in determining the best technological options

LCA Study on Sheep Milk Production in Sardinian Farms at Different Input Levels

This paper illustrates a Life Cycle Assessment (LCA) study carried out with the purposes of comparing the environmental impacts of sheep milk production from three different dairy farms in Sardinia, Italy, characterized by different production systems

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Toward eco-efficient production of natural nanofibers from industrial residue:eco-design and quality assessment

Abstract Conversion of bio-based industrial residues into high value-added products such as natural nanofibers is advantageous from an environmental and economic perspective, promoting resource efficiency along with the utilization of renewable materials. However, in order to employ the benefits of the raw material; its eco-efficient production should further be developed. Within this context, eco-design optimization through life cycle assessment (LCA) combined with life cycle costing (LCC) were applied to target eco-efficient production of natural nanofibers from carrot residue, along with quality assessment. The initial production steps included pretreatment combined mechanical nanofibrillation via ultrafine grinding, where the largest contributors to the environmental impact were identified as chemicals and energy. These were targeted by omitting the alkali pretreatment step and instead applying direct bleaching prior to nanofibrillation. After eco-design optimization, the yield increased while the energy, chemical, and water use significantly decreased. Therefore, a reduced environmental impact of more than 75% each for carbon footprint, freshwater ecotoxicity, and human toxicity was shown, along with a cost reduction of more than 50%. The use of carrot residue displayed an efficient conversion into natural nanofibers that was further promoted with the use of eco-design, yet with sustained functionality and nanoscaled dimensions, thus promoting resource-efficiency and natural nanofiber implementation in a wide range of promising bio-based applications

Addressing emerging risks using carbon capture and storage as an example

International audienceThe European iNTeg-Risk project is a large-scale integrated project aimed at improving the management of emerging risks related to new technologies in European industry. The project aims to build a new management paradigm for emerging risks as a set of principles supported by a common language, agreed tools and methods, and key performance indicators, all integrated into a single framework. It is using a number of Emerging Risk Representative Applications (ERRAs), or case studies, to inform the development of the framework; one of which concerns the carbon capture and storage (CCS) process. This paper describes the iNTeg-Risk CCS ERRA. Relevant hazards and properties of carbon dioxide are described and the emerging risks from CCS are discussed. Three new tools have been developed or trialled within the ERRA. These are: the DyPASI methodology for taking account of atypical (not usually identified) events during hazard identification; a methodology for including the time dimension in a risk assessment; and life-cycle approaches for risk management and communication. For CCS, the risk assessment needs to include both short-term potential accidents from capture, transport or injection, as well as very long-term risks from storage. Knowledge gaps which are generic to emerging risks are also identified

Overview of ERRA A1 on Carbon Capture and Storage

The iNTeg-Risk ERRA A1 on carbon capture and storage will be described with a focus on the aspects which can be generalised to other emerging risks. This includes two new methodologies which were trialled by the ERRA (the DyPASI methodology for identifying atypical events which was developed in ERRA C4; and life-cycle approaches using the iNTeg-Risk LCA guidance). It aIso includes a new methodology which was developed in ERRA A1 for including the time dimension in a risk assessment. Other generalisable aspects of the work done in the ERRA will aIso be included, for example work which has been done on risk communication for CCS, knowledge gaps, and KPIs. Knowledge gaps relevant to the regulation of CCS will be particularly covered. The work will a Iso be put in the context of the iNTeg-Risk ERMF

Carbon capture and storage : a case study of emerging risk issues in the iNTeg-Risk project

International audienc